How many people are living with ad worldwide is a high-volume search question about the global burden of Alzheimer disease (AD). The exact number changes as populations age and as diagnosis improves, but international dementia data show the scale clearly. The World Health Organization reports that about 57 million people worldwide were living with dementia in 2021, with nearly 10 million new cases each year. Alzheimer disease is the most common form and may account for roughly 60% to 70% of dementia cases.
How many people are living with AD worldwide?
Dementia is not a rare condition affecting only a small group of families. It is a major global health challenge involving tens of millions of people, and the number is expected to rise as populations live longer. The burden includes not only patients but also spouses, children, relatives, and professional caregivers.
For current international background, see the World Health Organization dementia fact sheet (opens in a new tab).
Why Alzheimer disease represents such a large share
Alzheimer disease is the most common cause of dementia. It progressively affects memory, thinking, language, judgment, and eventually the ability to carry out daily activities. Because the disease becomes more common with increasing age, demographic aging contributes substantially to the growing number of patients.
Prevalence is different from an individual diagnosis
Population statistics can describe how common Alzheimer disease is, but they cannot determine whether one person has it. Memory complaints can have many causes, including medication effects, depression, sleep disorders, thyroid problems, vitamin deficiencies, vascular disease, and other neurological conditions.
Patients with unexplained cognitive symptoms can begin with CubaHeal’s Neurological Disorders Medical Checkup or Memory Loss program to pursue a structured evaluation in Cuba.
The worldwide caregiver burden
Dementia often requires increasing help with medication, finances, meals, transportation, hygiene, safety, and supervision. This means prevalence statistics also represent millions of families adapting their lives around long-term care.
Comprehensive care can include caregiver education, rehabilitation, behavioral support, nutrition, mobility planning, and management of other medical conditions.
Cuba’s role in dementia and memory care
Cuba has developed services in neurology, geriatrics, rehabilitation, aging research, and biomedical science. Through CubaHeal, international families can submit records for review and explore care pathways that match the patient’s diagnosis and stage of illness.
The Dementia & NeuralCIM program provides an overview of CubaHeal’s approach. Families considering the Cuban NeuralCIM pathway can also review the NeuralCIM Neuro-Restorative Treatment program, with suitability determined by medical assessment.
Why early planning matters as case numbers grow
Earlier evaluation can help families establish a diagnosis, review medications, address safety, manage vascular and metabolic risk factors, and build a long-term support plan. Even when a progressive dementia cannot be cured, timely care can help preserve quality of life and reduce avoidable complications.
Research and healthy aging in Cuba
Cuba also has dedicated work in longevity and aging. CubaHeal’s Center for Research in Longevity, Aging and Health page describes one of the country’s resources focused on older-adult health and aging-related conditions.
Frequently asked questions
Are all 57 million people with dementia living with Alzheimer disease?
No. Dementia has multiple causes. Alzheimer disease accounts for the largest share, but vascular dementia, Lewy body dementia, frontotemporal disorders, and other conditions are also important.
Why are dementia numbers increasing?
Population aging is a major driver, along with improved recognition and diagnosis in many countries.
Can CubaHeal help families from outside Cuba?
Yes. CubaHeal coordinates medical-record review and access to relevant Cuban neurological and memory-care programs for international patients.
Global prevalence figures describe populations and should not be used to diagnose an individual patient.